Hospira, Par Pharma Settle Epinephrine False Ad Suit
A California federal judge signed off on a deal Tuesday to resolve claims brought by a unit of Par Pharmaceutical Inc. accusing Hospira Inc. of falsely marketing its products as being...To view the full article, register now.
Already a subscriber? Click here to view full article